Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis.
OBJECTIVE
To describe the characteristics of a previously overlooked devastating epileptic encephalopathy that presents as intractable bilateral perisylvian epilepsy starting with prolonged status epilepticus (SE) in normally developing school-aged children.


METHODS
Retrospective study over 7 years of all normally developing children admitted in our institution for a prolonged SE following non-specific febrile illness with at least one seizure recorded on EEG.


RESULTS
Fourteen children were included at a median age of 7.5 years (4-11) (median follow-up of 4 years (1-7)). Intractable SE lasted 4-60 days (median 30). CSF cell count was normal in five cases and moderately increased in the others. During SE, seizures were recorded in 11 patients and involved temporal lobes in 7; the other 4 patients exhibited perisylvian clinical features with secondary generalization. Intractable epilepsy followed SE in all cases without any latent period. Persisting seizures were recorded in 10 patients and involved temporo-perisylvian regions in 8, frontal regions in 2; 3 others had perisylvian ictal semiology. Spiking was bilateral in 10 cases. MRI showed bilateral hippocampal hypersignal and/or atrophy in 10 cases (extended to the neocortex in 3). All children had major cognitive sequelae. When feasible (six patients), detailed neuropsychology suggested fronto-temporal impairment.


CONCLUSIONS
Among so called grey matter encephalitis patients, we identified a recognizable pattern we propose to call Devastating Epileptic encephalopathy in School-age Children (DESC) that begins with prolonged SE triggered by fever of unknown cause, and persists as intractable perisylvian epilepsy with severe cognitive deterioration.
Neuropediatric Department, University Hospital, Bicêtre, France. yann.mikaeloff@tnn.aphp.fr
Y
Y
Mikaeloff
I
I
Jambaqué
L
L
Hertz-Pannier
A
A
Zamfirescu
C
C
Adamsbaum
P
P
Plouin
O
O
Dulac
C
C
Chiron
D000927:Anticonvulsants / Q000627:therapeutic use; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D003071:Cognition / Q000502:physiology*; D004351:Drug Resistance; D004569:Electroencephalography; D004660:Encephalitis / Q000134:cerebrospinal fluid / Q000209:etiology* / Q000503:physiopathology; D004827:Epilepsy / Q000188:drug therapy / Q000209:etiology*; D005335:Fever of Unknown Origin / Q000150:complications; D006801:Humans; D008279:Magnetic Resonance Imaging; D009483:Neuropsychological Tests; D011379:Prognosis; D012189:Retrospective Studies; D013226:Status Epilepticus / Q000150:complications*
D000927:Anticonvulsants; D002556:Cerebrospinal Fluid Proteins